Merck’s Keytruda gets FDA priority review for high-risk NMIBC

This article was originally published here

The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle

The post Merck’s Keytruda gets FDA priority review for high-risk NMIBC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply